Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01057121 · ClinicalTrials.gov registry record · Phase 1
Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma
A Phase 1 study of Recurrent Kaposi Sarcoma and AIDS-Related Kaposi Sarcoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 13
- Study locations
NCT01057121 is a Phase 1 study of Recurrent Kaposi Sarcoma and AIDS-Related Kaposi Sarcoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 38 participants. The trial reports 13 study locations across 10 states.
The verdict
NCT01057121, a Phase 1 study of Recurrent Kaposi Sarcoma and AIDS-Related Kaposi Sarcoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 13
- Study locations
Study Summary
This phase I/II trial studies the side effects and best dose of lenalidomide and to see how well it works in treating patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma (KS). Lenalidomide may stop the growth of tumor cells by blocking blood flow to the tumor.
Conditions Studied
Interventions
- DRUG Lenalidomide
Study Locations (13)
California
- UCLA Center for Clinical AIDS Research and Education - Los Angeles
- University of California San Diego - San Diego
- San Francisco General Hospital - San Francisco
Washington
- Virginia Mason Medical Center - Seattle
- Harborview Medical Center - Seattle
Florida
- University of Miami Miller School of Medicine-Sylvester Cancer Center - Miami
Hawaii
- Cancer Center of Hawaii-Hawaii AIDS Clinical Research Program - Honolulu
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital - Baltimore
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
New York
- Memorial Sloan-Kettering Cancer Center - New York
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2010-08-27 |
| Est. Completion | 2014-08-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01057121
The ClinicalTrials.gov registry entry for NCT01057121 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Recurrent Kaposi Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Lenalidomide is the first listed.
NCT01057121 reports 13 study locations spanning 10 distinct geographic areas - top geographies include California, Washington, Florida.
Frequently Asked Questions
What is clinical trial NCT01057121 about?
NCT01057121 is a clinical study titled "Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma". This phase I/II trial studies the side effects and best dose of lenalidomide and to see how well it works in treating patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma (KS). Lenalidomide may stop the growth of tumor cells by blocking blood flow to the tumor.
What is the current status of trial NCT01057121?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2010-08-27. Estimated completion is 2014-08-04.
What conditions does trial NCT01057121 study?
This clinical trial studies the following conditions: Recurrent Kaposi Sarcoma, AIDS-Related Kaposi Sarcoma.
What interventions are being tested in trial NCT01057121?
The interventions under investigation include: Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT01057121?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01057121 being conducted?
This trial has 13 study locations across California, Florida, Hawaii, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Kaposi Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.